体外研究 (In Vitro) |
Notoginsenoside R2 (20 μM; 24 h) 可保护 SH-SY5Y 细胞免受 6-OHDA (MS-Q40892) 诱导的细胞死亡,TUNEL 阳性细胞计数减少及总体凋亡率降低。 Notoginsenoside R2 (20 μM; 24 h) 可降低 6-OHDA 诱导的 SH-SY5Y 细胞、PC12 细胞及原代皮质神经元的 LDH 释放。 Notoginsenoside R2 (20 μM; 24 h) 可抑制 6-OHDA 诱导的 SH-SY5Y 细胞氧化应激,表现为细胞内 ROS 生成和 MDA 水平降低,逆转细胞线粒体膜去极化。 Notoginsenoside R2 (20 μM) 提高 SH-SY5Y 细胞中 HO-1、GSH-PX 和 GR 的活性,且预孵育 24 h 可逆转 6-OHDA 诱导的上述酶活性降低及核内 Nrf2 聚集水平下降。 Notoginsenoside R2 (20 μM; 4-24 h) 可激活 SH-SY5Y 细胞中的 MEK1/2-ERK1/2 信号通路,进而诱导下游 P90RSK 和 Nrf2 的激活,后者可介导抑制 6-OHDA 诱导的凋亡蛋白表达;而上述通路的激活依赖于 MEK1/2-ERK1/2 信号传导,但不依赖于 JNK、p38 或 PI3K/Akt 信号传导。 Notoginsenoside R2 (10-30 μM) 可剂量依赖性地减轻 Aβ25-35 (MS-O24173) 诱导的原代大鼠皮质神经元凋亡,降低活化型 caspase-3、miR-27a 表达水平,并下调 COX-2 的表达,上调 SOX8 的 mRNA 和蛋白表达,上调总 β-catenin 蛋白及核内 β-catenin 蛋白的表达。 Notoginsenoside R2 (10-40 μM; 24 h) 可通过抑制 c-Src 活化,减轻高血糖与棕榈酸 (HGPA) 刺激的 HK-2 细胞中的脂质蓄积、氧化应激、线粒体功能障碍及细胞凋亡。 Notoginsenoside R2 (10-100 μM; 24 h) 抑制 HSC-T6 细胞增殖。 Notoginsenoside R2 (20-30 μM; 24 h) 下调 HSC-T6 细胞中 α-SMA 和 COL-I 的 mRNA 和蛋白表达。 Notoginsenoside R2 (20 μM; 24 h) 可在 HSC-T6 细胞中下调纤维化标志物 (α-SMA、COL-I、Desmin、TIMP-1),并上调衰老标志物 (p16、p21、p53)。 Notoginsenoside R2 (20 μM; 24 h) 抑制 HSC-T6 细胞中的 JAK/STAT3 信号通路。 Notoginsenoside R2 (20 μM; 24 h) 抑制 HSC-T6 细胞中促炎细胞因子的 mRNA 表达。 Notoginsenoside R2 (20 μM; 24 h) 上调 HSC-T6 细胞中 SASP 组分的 mRNA 表达。 Notoginsenoside R2 (20 μM; 24 h) 可降低 HSC-T6 细胞内的 ROS 水平。 Notoginsenoside R2 (20 μM; 24 h) 诱导 HSC-T6 细胞发生衰老。
Apoptosis Analysis
| Cell Line: |
SH-SY5Y human neuroblastoma cells |
| Concentration: |
20 μM |
| Incubation Time: |
24 h (pre-incubation) |
| Result: |
Significantly reduced the number of TUNEL-positive cells and the overall apoptosis rate induced by 6-OHDA. Had no effect on apoptosis rate or TUNEL-positive cell count when treated alone. |
Western Blot Analysis
| Cell Line: |
SH-SY5Y human neuroblastoma cells |
| Concentration: |
20 μM |
| Incubation Time: |
4 h, 8 h, 16 h, 20 h, 24 h |
| Result: |
Increased phosphorylation of P90RSK, BAD, MEK1/2, and ERK1/2, and enhanced nuclear Nrf2 accumulation in a time-dependent manner when treated alone, with MEK1/2 phosphorylation peaking at 16 h and ERK1/2 phosphorylation peaking at 20 h. Blocked 6-OHDA-induced increases in cytochrome c release, cleaved caspase-9, and cleaved caspase-3, and reversed 6-OHDA-induced reductions in p-BAD levels when pre-incubated for 24 h. Induced P90RSK phosphorylation and nuclear Nrf2 accumulation were prevented by pre-incubation with MEK1/2 inhibitor PD98059, while JNK, p38, or PI3K/Akt inhibitors had no effect. Induced phosphorylation of ERK1/2, P90RSK, and BAD, as well as nuclear Nrf2 accumulation and increases in HO-1, GSH-PX, and GR activities were blocked by MEK1/2 or ERK1/2 siRNA transfection. Induced increases in HO-1, GSH-PX, and GR activities were blocked by Nrf2 siRNA transfection. |
Cell Viability Assay
| Cell Line: |
HSC-T6 hepatic stellate cells |
| Concentration: |
10, 20, 40, 80, 100 μM |
| Incubation Time: |
24 h |
| Result: |
Suppressed HSC-T6 cell proliferation in a dose-dependent manner at concentrations of 40-100 μM. Caused statistically significant reductions in cell viability at 80 μM and 100 μM relative to the normal control. |
Real Time qPCR
| Cell Line: |
HSC-T6 cells |
| Concentration: |
20, 30 μM |
| Incubation Time: |
24 h |
| Result: |
Caused a marked reduction in mRNA expression of α-SMA relative to the normal control. Caused a marked reduction in mRNA expression of COL-I relative to the normal control. |
Immunofluorescence
| Cell Line: |
HSC-T6 cells |
| Concentration: |
20 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly decreased the area of α-SMA staining in HSC-T6 cells relative to the normal control. Significantly decreased the area of COL-I staining in HSC-T6 cells relative to the normal control. |
Western Blot Analysis
| Cell Line: |
HSC-T6 cells |
| Concentration: |
20 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly reduced protein expression of α-SMA relative to the normal control. Significantly reduced protein expression of COL-I) relative to the normal control. Significantly reduced protein expression of Desmin relative to the normal control. Significantly reduced protein expression of TIMP-1 relative to the normal control. Significantly increased protein expression of p16 relative to the normal control. Significantly increased protein expression of p21 relative to the normal control. Significantly increased protein expression of p53 relative to the normal control.\nSignificantly reduced the phosphorylation of JAK relative to the normal control. Significantly reduced the phosphorylation of STAT3 relative to the normal control. Left total JAK and STAT3 protein levels unchanged. |
Real Time qPCR
| Cell Line: |
HSC-T6 cells |
| Concentration: |
20 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly reduced mRNA expression of pro-inflammatory mediators including IL-6, IL-1β, CCL2, IL-8, and TNF-α relative to the normal control.\nSignificantly upregulated mRNA expression of SASP components including p16, p21, p53, and MMP10 relative to the normal control. |
|
体内研究 (In Vivo) |
Notoginsenoside R2 (250 mg/kg,腹腔注射,每日一次,连续 20 周) 可改善自发性阿尔茨海默病模型 SAMP8 小鼠的认知功能,减少海马神经元凋亡,并调控凋亡及炎症相关蛋白的表达。 Notoginsenoside R2 (250 mg/kg;腹腔注射;每日一次;连续 20 周) 可改善 Aβ25-35 诱导的阿尔茨海默病大鼠的认知功能,减少海马神经元凋亡,并调控凋亡及炎症相关蛋白的表达。 Notoginsenoside R2 (20-40 mg/kg,每日口服,持续 8 周) 可改善糖尿病肾病模型 db/db 小鼠的肾功能障碍、组织病理学损伤、脂质蓄积、氧化应激、线粒体功能障碍及细胞凋亡,其作用部分通过抑制 c-Src 的激活实现。 Notoginsenoside R2 (6.25-25 μM; 于 TAA 预处理 72 小时后给药) 可通过 STAT3 依赖性途径减轻氧化应激、炎症反应并诱导肝星状细胞衰老,从而呈剂量依赖性地缓解斑马鱼中由 TAA (MS-A54832) 诱导的肝纤维化。
| Animal Model: |
SAMP8 (male, 3-month-old, 20-30 g, spontaneous Alzheimer's disease model); SAMR1 (male, normal aging control) |
| Dosage: |
250 mg/kg |
| Administration: |
i.p.; daily; 20 consecutive weeks |
| Result: |
Reduced learning reaction time to 25.23 s. Reduced learning error time to 4.52. Increased memory reaction time to 180 s. Reduced memory error time to 5.41. Alleviated hippocampal neuronal disorganization and loss of pyramidal cells. Reduced TUNEL-positive apoptotic cells compared to the AD group. Decreased cleaved caspase-3 and COX-2 protein expression compared to the AD group. Increased SOX8 and β-catenin protein expression compared to the AD group. |
| Animal Model: |
Sprague-Dawley (male, 18-20 months-old, 200-220 g, Aβ25-35-induced Alzheimer's disease model via bilateral hippocampal injection); Sprague-Dawley (male, 3-6 months-old, control) |
| Dosage: |
250 mg/kg |
| Administration: |
i.p.; daily; 20 consecutive weeks |
| Result: |
Reduced learning reaction time to 25.23 s. Reduced learning error time to 3.98. Increased memory reaction time to 182.32 s. Reduced memory error time to 6.23. Restored hippocampal neuronal structure compared to the Aβ25-35-treated group. Reduced TUNEL-positive apoptotic cells compared to the Aβ25-35-treated group. Decreased cleaved caspase-3 and COX-2 protein expression compared to the Aβ25-35-treated group. Increased SOX8 and β-catenin protein expression compared to the Aβ25-35-treated group. |
| Animal Model: |
C57BKS/Lepr db/db (male, 7-8 weeks old, spontaneous diabetic nephropathy with elevated urine albumin-to-creatinine ratios) |
| Dosage: |
20 mg/kg/day; 40 mg/kg/day |
| Administration: |
p.o.; daily; 8 weeks |
| Result: |
Reduced urine albumin-to-creatinine ratios (ACR) levels compared to untreated db/db mice, with 40 mg/kg dose causing greater reduction than positive control Losartan. Significantly lowered serum creatinine (Scr) and blood urea nitrogen (BUN) levels relative to untreated db/db mice at 40 mg/kg dose; significantly reduced Scr levels at 20 mg/kg dose. Significantly reduced serum total cholesterol (TC) levels compared to untreated db/db mice at 20 mg/kg dose; reduced TC levels to a greater, statistically significant extent at 40 mg/kg dose. Left serum triglyceride (TG) levels unchanged with either dose. Unaffected liver function markers (ALT, AST), indicating no liver toxicity. Ameliorated renal histopathological abnormalities including mesangial expansion, glycogen deposition, collagen fiber deposition, and podocyte foot process effacement, and significantly reduced renal expression of fibrosis-related proteins (fibronectin, vimentin, α-SMA) at both doses. Significantly reduced intrarenal lipid accumulation (measured by Oil Red O staining and renal triglyceride content), and suppressed renal expression of phosphorylated c-Src (Tyr416), phosphorylated JNK, phosphorylated STAT1, and CD36 at both doses. Reduced renal malondialdehyde (MDA) levels, increased superoxide dismutase (SOD), glutathione (GSH), glutathione reductase (GR), catalase (CAT), and ATP levels relative to untreated db/db mice at both doses. Downregulated renal expression of mitochondrial fission proteins Drp1 and Fis1, and upregulated the mitochondrial fusion protein Mfn2 at both doses. Reduced renal TUNEL-positive apoptotic cells, lowered expression of pro-apoptotic proteins (Bax, cleaved-caspase-3), and increased expression of the anti-apoptotic protein Bcl-2 at both doses. |
| Animal Model: |
wild-type AB strain; transgenic Tg(lfabp10α:eGFP) strain (2-day post-fertilization larvae) |
| Dosage: |
6.25 μM; 12.5 μM; 25 μM (general); 25 μM (STAT3-knockdown zebrafish) |
| Administration: |
administered following 72-hour TAA preconditioning |
| Result: |
Caused no notable morphological abnormalities, developmental delays, or hatching rate differences compared to untreated controls at 6.25 μM, 12.5 μM, and 25 μM. Significantly mitigated TAA-induced hepatic damage (reduced intercellular gaps, hepatocellular enlargement, and vacuolation) as observed via H&E staining, and dose-dependently reduced mRNA levels of fibrotic markers α-SMA and COL-I at 6.25 μM, 12.5 μM, and 25 μM. Significantly reduced hepatic reactive oxygen species (ROS) levels, reduced mRNA expression of pro-inflammatory cytokines (IL-6, IL-1β, CCL2, IL-8, TNF-α), reduced STAT3 protein levels and JAK/STAT3 pathway gene expression, and significantly upregulated protein and mRNA levels of senescence biomarkers p16 and p21, plus SASP components including p53 at 25 μM. Lost antifibrotic effects in STAT3-knockdown zebrafish: no longer mitigated hepatic vacuolation/tissue disorganization, failed to reduce α-SMA and COL-I mRNA levels, showed diminished ROS suppression, lost anti-inflammatory activity, and no longer upregulated senescence biomarkers p16 and p21 or SASP components at 25 μM. |
|